Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600‐mutated melanoma. (8th May 2017)

• Record Type: Journal Article
• Authors: Amann, V.C.; Hoffmann, D.; Mangana, J.; Dummer, R.; Goldinger, S.M.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 31:Number 10(2017)
• Page Start: 1638
• Page End: 1640
• Publication Date: 2017-05-08
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.14268
• Languages: English
• ISSNs: 0926-9959

Abstract

Abstract: Background: The combination treatment with BRAF and MEK inhibitors is amongst the current standard of care for stage IIIC/IV BRAF‐mutated melanoma. However, therapeutic options are limited once patients have progressed upon both targeted and immunotherapy. Objective: To investigate whether retreatment with BRAF and MEK inhibitor combination is an option for patients with metastatic BRAF‐mutated melanoma upon previous progression on kinase inhibitors. Methods: Two patients with metastatic BRAF‐mutated melanoma were rechallenged with BRAF and MEK inhibitor combination after progression on targeted therapy and subsequent immunotherapy with anti‐CTLA‐4 and anti‐PD‐1 antibodies. Results: Both patients responded to retreatment. Responses were limited to a few months and associated with a considerable increase in quality of life. Conclusion: Retreatment with BRAF and MEK inhibitors may present a feasible treatment option upon progression on both kinase inhibitors and immunotherapy, and should be considered when all other treatment options have been exhausted.